Helicos BioSciences's EPS (Basic) for the
six
months ended in Dec. 2011 was €-0.05.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2011 was €-0.05.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
Helicos BioSciences EPS (Diluted) Historical Data
The historical data trend for Helicos BioSciences's EPS (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Helicos BioSciences's EPS (Diluted)
For the Drug Manufacturers - Specialty & Generic subindustry, Helicos BioSciences's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Helicos BioSciences's PE Ratio Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Helicos BioSciences's PE Ratio distribution charts can be found below:
* The bar in red indicates where Helicos BioSciences's PE Ratio falls into.
Helicos BioSciences EPS (Diluted) Calculation
EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.
Helicos BioSciences's Diluted EPS for the fiscal year that ended in Dec. 2011 is calculated as
For stock reported annually, GuruFocus uses latest annual data as the TTM data. EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2011 was €-0.05
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Helicos BioSciences EPS (Diluted) Related Terms
Thank you for viewing the detailed overview of Helicos BioSciences's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.
Helicos BioSciences (FRA:HB4) Business Description
Helicos BioSciences Corp is incorporated in the state of Delaware and was incorporated on May 9, 2003. It is a life sciences company focused on genetic analysis technologies for the research, drug discovery and clinical diagnostics markets. The Company's products are based on its proprietary True Single Molecule Sequencing (tSMS) technology which enables rapid analysis of large quantities of genetic material by directly sequencing single molecules of DNA or single DNA copies of RNA. The Company's Helicos Genetic Analysis Platform is designed to obtain sequencing information by repetitively performing a cycle of biochemical reactions on individual DNA molecules and imaging the results after each cycle. The platform consists of an instrument called the HeliScope Single Molecule Sequencer, an image analysis computer tower called the HeliScope Analysis Engine, associated reagents, which are chemicals used in the sequencing process, and disposable supplies. The Company is subject, both directly and indirectly, to the adverse impact of existing and potential future government regulation of its operations and markets.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:HB4 has been successfully added to your